Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer

Sideris, Spyridon; Aoun, Fouad; Zanaty, Marc; Martinez, Nieves Chanza; Latifyan, Sofia; Awada, Ahmad; Gil, Thierry

doi:10.3892/mco.2016.821

Cited by 34 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Taxanes have been shown to be active as treatment options for urothelial bladder cancer. [115][116][117][118] Based on these results, several groups are exploring 2-and 3-drug combinations using these agents, with and without cisplatin. A randomized phase III trial was conducted to compare GC and GC plus paclitaxel in 626 patients with locally advanced or metastatic urothelial cancer.…”

Section: Chemotherapy For Metastatic Diseasementioning

confidence: 99%

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Flaig

Spiess

Agarwal

et al. 2020

Journal of the National Comprehensive Cancer Network

489

389

View full text Add to dashboard Cite

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

show abstract

Section: Chemotherapy For Metastatic Diseasementioning

confidence: 99%

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Flaig

Spiess

Agarwal

et al. 2020

Journal of the National Comprehensive Cancer Network

489

389

View full text Add to dashboard Cite

show abstract

“…Combination chemotherapy has been shown to reduce the recurrence rate of BUC and to improve patients' survival (4). Treatment with the microtubule stabilizing agent, paclitaxel has also proven to be an effective therapy against BUC (5,6). Recent phase III clinical trials have found that a PCG (paclitaxel plus cisplatin plus gemcitabine) regimen, consisting of the addition of paclitaxel to a standard chemotherapy regimen of cisplatin plus gemcitabine (GC), can improve the overall response rate and overall survival rate of patients with BUC (7).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy

Zeng

Liu

Cao

et al. 2018

Clinical Cancer Research

View full text Add to dashboard Cite

Regulated in development and DNA damage response-1 (REDD1) is a stress-related protein and is involved in the progression of cancer. The role and regulatory mechanism of REDD1 in bladder urothelial carcinoma (BUC), however, is yet unidentified. The expression of REDD1 in BUC was detected by Western blot analysis and immunohistochemistry (IHC). The correlation between REDD1 expression and clinical features in patients with BUC were assessed. The effects of REDD1 on cellular proliferation, apoptosis, autophagy, and paclitaxel sensitivity were determined both and Then the targeted-regulating mechanism of REDD1 by miRNAs was explored. Here the significant increase of REDD1 expression is detected in BUC tissue, and REDD1 is first reported as an independent prognostic factor in patients with BUC. Silencing REDD1 expression in T24 and EJ cells decreased cell proliferation, increased apoptosis, and decreased autophagy, whereas the ectopic expression of REDD1 in RT4 and BIU87 cells had the opposite effect. In addition, the REDD1-mediated proliferation, apoptosis, and autophagy are found to be negatively regulated by miR-22 , which intensify the paclitaxel sensitivity via inhibition of the well-acknowledged REDD1-EEF2K-autophagy axis. AKT/mTOR signaling initially activated or inhibited in response to silencing or enhancing REDD1 expression and then recovered rapidly. Finally, the inhibited REDD1 expression by either RNAi or miR-22 sensitizes BUC tumor cells to paclitaxel in a subcutaneous transplant carcinoma model REDD1 is confirmed as an oncogene in BUC, and antagonizing REDD1 could be a potential therapeutic strategy to sensitize BUC cells to paclitaxel. .

show abstract

“…Unfortunately, as stated in the introduction, there are currently no established second-line chemotherapy regimens for cisplatin-resistant UC. However, there are several reports that paclitaxel-based chemotherapy has had some effectiveness in terms of improvement of quality of life and prognosis in patients with cisplatin-resistant UC (18,23). In recent years, immune-checkpoint inhibitors have been reported as a novel treatment modality for patients with advanced UC, including platinum-treated advanced UC (21,22).…”

Section: Discussionmentioning

confidence: 99%